Evidence map›Paper›PMID 37603845›Full record

SynthesisStem cells translational medicine2023

Allogeneic Cell Therapy Applications in Neonates: A Systematic Review.

Abdul Razak, Donna Lei, Courtney A McDonald, Rod W Hunt, Suzanne L Miller, Atul Malhotra

Open access · goldAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Stem cells translational medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Abdul RazakDepartment of Paediatrics, Monash University, Melbourne, VIC, Australia.ORCID 0000-0002-6185-3694
Donna LeiDepartment of Paediatrics, Monash University, Melbourne, VIC, Australia.
Courtney A McDonaldThe Ritchie Centre, Hudson Institute of Medical Research, Melbourne, VIC, Australia.
Rod W HuntDepartment of Paediatrics, Monash University, Melbourne, VIC, Australia.
Suzanne L MillerThe Ritchie Centre, Hudson Institute of Medical Research, Melbourne, VIC, Australia.
Atul MalhotraDepartment of Paediatrics, Monash University, Melbourne, VIC, Australia.ORCID 0000-0001-9664-4182
Hudson Institute of Medical Research · AUMonash University · AU

Funding

Lions Cord Blood FoundationMedical Research Future Fund of AustraliaMonash UniversityNational Health and Medical Research Council of Australia
6 · The paper itself

Abstract

backgroundNeonatal cell therapy applications are increasing; however, data on allogeneic cell therapy are limited.

objectiveTo summarize evidence on allogeneic cell therapy in term and preterm neonates.

methodsCochrane Central Register of Controlled Trials, Embase, Ovid Medline, and various registries were searched for studies investigating the safety, feasibility, and efficacy of allogeneic cell therapy in neonates. Two authors independently selected the articles, extracted data, and assessed the risk of bias.

resultsTwelve published (153 infants) and 21 ongoing studies were included. These studies predominantly sourced allogeneic cells from umbilical cord blood (UCB). Mesenchymal stromal cells (MSCs) were the main cell type used (134 of 153 infants); others included UCB-derived total nucleated cells (TNCs) and human amnion epithelial cells (hAECs). Applications included bronchopulmonary dysplasia (BPD; 113 infants), Krabbe disease (13 infants), intraventricular haemorrhage (10 infants), perinatal arterial ischemic stroke (10 infants), hypoxic-ischaemic encephalopathy (6 infants), and necrotizing enterocolitis (1 infant). Nine out of 12 studies did not report any serious adverse events (SAEs) related to cell administration. Three studies reported SAEs, such as graft versus host disease (GVHD) in 5 infants (UCB-derived TNCs for Krabbe disease); and transient cardiorespiratory compromise in 1 infant (hAECs for BPD). Data on efficacy outcomes were limited.

conclusionThe safety and feasibility of allogeneic cell therapy applications in neonates are available, mainly from the use of MSCs. Further safety data for other cell types are required, and the risk of GVHD in different settings needs to be determined. Efficacy studies are largely lacking for all cell types. PROTOCOL REGISTRATION: The protocol was registered with PROSPERO (registration number CRD42023397876), the international prospective register for systematic reviews (https://www.crd.york.ac.uk/PROSPERO).

Indexed as

Cell- and Tissue-Based TherapyFetal BloodHumansInfant, NewbornMesenchymal Stem Cell TransplantationTransplantation, Homologousallogeneiccell therapyhuman amnion epithelial cellinfantmesenchymal stromal cellneonatesprematurepretermtotal nucleated cell

Identifiers

PMID37603845
PMCPMC10552935
OpenAlexW4386025856

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.